Pfizer (NYSE:PFE – Get Free Report) issued its earnings results on Tuesday. Here are the key takeaways from Pfizer’s conference call:Get Pfizer alerts:Positive Sentiment: Pfizer raised its 2026 revenue guidance midpoint by $500 million to $60.5–$62.5 billion, despite lowering expected COVID revenue to approximately $4 billion. Positive Sentiment: Pfizer expanded its cost-reduction targets, now expecting approximately $9.7 billion in total net savings through 2029, including additional savings from technology, simplification, and manufacturing optimization. Neutral Sentiment: Pfizer emphasized potentially important longer-term catalysts, including its obesity programs, with 10 planned Phase III studies for berobenatide/nirubenatide-related therapies and an initial approval target beginning in 2028. Pfizer Stock Up 0.6%PFE stock traded up $0.16 on Wednesday, hitting $25.57.